Aurigene Discovery Technologies Limited

Curis, Inc.

Aurigene Oncology Limited

Pottayil Govindan N Sasikumar

Muralidhara Ramachandra

Seetharamaiah Setty S Naremaddepalli

Timothy L Wyant

Raghuveer K Ramachandra

Adam S Lazorchak

Seetharamaiah Setty Sudarshan Naremaddepalli

Nagaraj Gowda

The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.

Crystalline forms of 3-substituted 1,2,4-oxadiazole

The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.

Conjoint therapies for immunomodulation

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.

Dual inhibitors of TIM-3 and PD-1 pathways

The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

Growing community of inventors

Bengaluru, India

Pottayil Govindan N Sasikumar